Comparison

Exenatide vs. VK2735

Two peptides side-by-side — identity, evidence base, legal status and known adverse events.

Identity

Mechanism of action

Exenatide

Exenatide is a 39-amino-acid peptide with about 53% sequence homology to human GLP-1. A glycine substitution at position 2 prevents dipeptidyl-peptidase-IV cleavage and extends the half-life from native GLP-1 (minutes) to about 2.4 hours. GLP-1 receptor activation glucose-dependently stimulates insulin secretion, inhibits glucagon and delays gastric emptying.

VK2735

VK2735 activates both the GLP-1 and the GIP receptor — a dual mechanism similar to that of tirzepatide, suppressing appetite and food intake.

Evidence base

Highest evidence

Human RCT

Studies

of which in humans

Effects recorded

Open conflicts

Documented adverse events

Legal status

Country	Exenatide	VK2735
Germany	Prescription	Unapproved
United States	Prescription	Unapproved

Full entries

Frequently asked questions

What is the difference between Exenatide and VK2735?: Exenatide is classified as "Metabolic", while VK2735 is classified as "Metabolic". Exenatide: Synthetic version of exendin-4, originally isolated from the saliva of the Gila monster (Heloderma suspectum). First GLP-1 receptor agonist, FDA-approved 2005 as Byetta. Weekly depot form Bydureon approved 2012. VK2735: VK2735 is a dual GLP-1/GIP receptor agonist from Viking Therapeutics, in development in both subcutaneous and oral forms for obesity. This page contrasts both neutrally and source-based — with no usage or dosing recommendation.
Which peptide is better supported by science, Exenatide or VK2735?: The highest available evidence level is "Human RCT" for Exenatide and "Human RCT" for VK2735. A higher evidence level means more robust data, but says nothing about suitability for an individual. The full body of evidence is on each peptide's own page.
What is the legal status of Exenatide and VK2735 in Germany and the United States?: Germany: Exenatide — Prescription, VK2735 — Unapproved. United States: Exenatide — Prescription, VK2735 — Unapproved. These are factual summaries with source and review date on the individual pages.

Country

Exenatide

VK2735

Germany

Prescription

Unapproved

United States

Prescription

Unapproved

Frequently asked questions

What is the difference between Exenatide and VK2735?

Exenatide is classified as "Metabolic", while VK2735 is classified as "Metabolic". Exenatide: Synthetic version of exendin-4, originally isolated from the saliva of the Gila monster (Heloderma suspectum). First GLP-1 receptor agonist, FDA-approved 2005 as Byetta. Weekly depot form Bydureon approved 2012. VK2735: VK2735 is a dual GLP-1/GIP receptor agonist from Viking Therapeutics, in development in both subcutaneous and oral forms for obesity. This page contrasts both neutrally and source-based — with no usage or dosing recommendation.

Which peptide is better supported by science, Exenatide or VK2735?

The highest available evidence level is "Human RCT" for Exenatide and "Human RCT" for VK2735. A higher evidence level means more robust data, but says nothing about suitability for an individual. The full body of evidence is on each peptide's own page.

What is the legal status of Exenatide and VK2735 in Germany and the United States?

Germany: Exenatide — Prescription, VK2735 — Unapproved. United States: Exenatide — Prescription, VK2735 — Unapproved. These are factual summaries with source and review date on the individual pages.